MARKET

ATHX

ATHX

Athersys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8512
+0.0276
+3.35%
Opening 14:47 01/20 EST
OPEN
0.8300
PREV CLOSE
0.8236
HIGH
0.8999
LOW
0.8300
VOLUME
560.30K
TURNOVER
--
52 WEEK HIGH
3.030
52 WEEK LOW
0.8100
MARKET CAP
200.23M
P/E (TTM)
-2.0695
1D
5D
1M
3M
1Y
5Y
Implied Volatility Surging for Athersys (ATHX) Stock Options
Zacks.com · 01/02 00:26
Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal
Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial 
Benzinga · 11/30/2021 15:06
BRIEF-Athersys Publishes Report Of Clinical Trial For Acute Respiratory Distress Syndrome Treatment
reuters.com · 11/30/2021 12:41
Athersys gains on publication of cell therapy study results against respiratory disorder
Athersys (NASDAQ:ATHX) has added ~19.6% in the pre-market on above-average volume after the company announced the peer-reviewed publication of results from a placebo-controlled study for its MultiStem cell therapy in patients with
Seekingalpha · 11/30/2021 12:39
Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 11/24/2021 17:00
Why Investors Should Hold on to Universal Health (UHS) Stock
Zacks.com · 11/24/2021 15:17
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Zacks · 11/22/2021 16:54
SAVA, GTEC and RAAS among mid-day movers
Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +1...
Seekingalpha · 11/19/2021 17:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
75.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATHX stock price target is 4.563 with a high estimate of 7.00 and a low estimate of 1.250.
High7.00
Average4.563
Low1.250
Current 0.8512
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 200
Institutional Holdings: 57.71M
% Owned: 24.53%
Shares Outstanding: 235.24M
TypeInstitutionsShares
Increased
44
2.69M
New
16
448.21K
Decreased
33
2.20M
Sold Out
13
492.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.54%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Non-Executive Chairman/Independent Director
Ismail Kola
President/Chief Executive Officer/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Director
Hardy Kagimoto
Director
Kenneth Traub
Independent Director
Katherine Kalin
Independent Director
Lorin Randall
Independent Director
Baiju Shah
Independent Director
Jane Wasman
Independent Director
Jack Wyszomierski
No Data
About ATHX
Athersys, Inc. is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is a biologic product that is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The Company is conducting Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The Company's programs in the clinical development-stage include ischemic stroke, Acute respiratory distress syndrome (ARDS) and trauma.

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.